Great news!
The SMC has recommended both elascestrant, and capivasertib with fulvestrant for use on the NHS in Scotland for eligible metastatic breast cancer patients: breastcancernow.org/about-us/med...
The SMC has recommended both elascestrant, and capivasertib with fulvestrant for use on the NHS in Scotland for eligible metastatic breast cancer patients: breastcancernow.org/about-us/med...
We respond to SMC decision recommending elacestrant & capivasertib with fulvestrant
Melanie Sturtevant, associate director of policy, evidence and influencing at Breast Cancer Now, said:
breastcancernow.org
September 8, 2026 at 8:39 AM
Great news!
The SMC has recommended both elascestrant, and capivasertib with fulvestrant for use on the NHS in Scotland for eligible metastatic breast cancer patients: breastcancernow.org/about-us/med...
The SMC has recommended both elascestrant, and capivasertib with fulvestrant for use on the NHS in Scotland for eligible metastatic breast cancer patients: breastcancernow.org/about-us/med...
Read the Phase 1b/2 Study: Durvalumab + Paclitaxel ± Capivasertib or Oleclumab in mTNBC (NCT03742102), in Clinical Cancer Research. buff.ly/84bWT8W
September 3, 2026 at 1:55 PM
Read the Phase 1b/2 Study: Durvalumab + Paclitaxel ± Capivasertib or Oleclumab in mTNBC (NCT03742102), in Clinical Cancer Research. buff.ly/84bWT8W
RRIDs were included in this in Clinical Cancer Research paper. We value the author's support of reproducibility. #BetterScience #accelerateopenscience #methodsmatter
Durvalumab plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer
Read the full paper: Durvalumab plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer
doi.org
August 28, 2026 at 7:02 AM
RRIDs were included in this in Clinical Cancer Research paper. We value the author's support of reproducibility. #BetterScience #accelerateopenscience #methodsmatter
RRIDs were included in this in Molecular Cancer Therapeutics paper. We value the author's support of reproducibility. #RRID #STMpublishing #ReproducibleResearch
Capivasertib combines with trastuzumab deruxtecan to enhance anti-tumour activity in HER2-positive and HER2-low tumours
Read the full paper: Capivasertib combines with trastuzumab deruxtecan to enhance anti-tumour activity in HER2-positive and HER2-low tumours
doi.org
July 10, 2026 at 7:01 AM
RRIDs were included in this in Molecular Cancer Therapeutics paper. We value the author's support of reproducibility. #RRID #STMpublishing #ReproducibleResearch
#NEO NeoGenomics Launches FDA-Approved PTEN IHC Companion Diagnostic for Prostate Cancer
https://www.stocktitan.net/news/NEO/neo-genomics-launches-fda-approved-pten-ihc-companion-diagnostic-for-w0nyu4f06ipv.html
https://www.stocktitan.net/news/NEO/neo-genomics-launches-fda-approved-pten-ihc-companion-diagnostic-for-w0nyu4f06ipv.html
NeoGenomics Launches FDA-Approved PTEN IHC Companion Diagnostic for Prostate Cancer
NeoGenomics (NASDAQ: NEO) launched PTEN IHC CDx, the first FDA-approved immunohistochemistry companion diagnostic for patients with prostate adenocarcinoma. The tissue-based test detects PTEN protein loss to help identify patients who may be eligible for AstraZeneca’s targeted therapy TRUQAP (capivasertib).The assay is performed by NeoGenomics pathologists across its national oncology laboratory network and is available as a standalone test or integrated into NEO PanTracer Pro for prostate cancer, a comprehensive molecular workup. Prostate cancer affects over 300,000 men annually in the US, with about 8,750 mAPMN/S cases estimated to be PTEN-deficient each year.
www.stocktitan.net
July 9, 2026 at 11:05 AM
#NEO NeoGenomics Launches FDA-Approved PTEN IHC Companion Diagnostic for Prostate Cancer
https://www.stocktitan.net/news/NEO/neo-genomics-launches-fda-approved-pten-ihc-companion-diagnostic-for-w0nyu4f06ipv.html
https://www.stocktitan.net/news/NEO/neo-genomics-launches-fda-approved-pten-ihc-companion-diagnostic-for-w0nyu4f06ipv.html
📸 Image generated using Sora by OpenAI.
Article link: www.fda.gov/drugs/resour...
Article link: www.fda.gov/drugs/resour...
FDA approves capivasertib with abiraterone and prednisone for PTEN-def
On June 12, 2026, the Food and Drug Administration approved capivasertib (Truqap, AstraZeneca) in combination with abiraterone and prednisone for adults with metastatic androgen pathway modulation-naï...
www.fda.gov
June 22, 2026 at 1:18 PM
📸 Image generated using Sora by OpenAI.
Article link: www.fda.gov/drugs/resour...
Article link: www.fda.gov/drugs/resour...
The @fda.gov has approved capivasertib in combination with abiraterone and prednisone for patients with PTEN-deficient metastatic androgen pathway modulation-naïve or -sensitive prostate cancer.
Link in the comments 👇
#Oncology #ProstateCancer #PrecisionOncology #AKT #PTEN
Link in the comments 👇
#Oncology #ProstateCancer #PrecisionOncology #AKT #PTEN
June 22, 2026 at 1:17 PM
The @fda.gov has approved capivasertib in combination with abiraterone and prednisone for patients with PTEN-deficient metastatic androgen pathway modulation-naïve or -sensitive prostate cancer.
Link in the comments 👇
#Oncology #ProstateCancer #PrecisionOncology #AKT #PTEN
Link in the comments 👇
#Oncology #ProstateCancer #PrecisionOncology #AKT #PTEN
OncoPharm
Updates on capivasertib, belzutifan, talquetamab, & durvalumab
OncoPharm · Episode
open.spotify.com
June 22, 2026 at 12:50 PM
OncoPharm
Feed: "Oncology News, Insights, Stories by OncoDaily"
Published on Friday, June 19, 2026
Published on Friday, June 19, 2026
FDA Approved Capivasertib Plus Abiraterone and Prednisone for PTEN-Deficient Metastatic Prostate Cancer
FDA Approved Capivasertib Plus Abiraterone and Prednisone for PTEN-Deficient Metastatic Prostate Cancer / abiraterone, cancer, cancer care, Cancer research,
oncodaily.com
June 19, 2026 at 4:32 PM
Feed: "Oncology News, Insights, Stories by OncoDaily"
Published on Friday, June 19, 2026
Published on Friday, June 19, 2026
📢 New @fda.gov approval for #capivasertib in advanced #ProstateCancer.
The drug, made possible by decades of research at the ICR, helps delay progression in patients with PTEN-deficient disease – an aggressive form with poor outcomes.
Read more ⤵️
www.icr.ac.uk/about-us/icr...
The drug, made possible by decades of research at the ICR, helps delay progression in patients with PTEN-deficient disease – an aggressive form with poor outcomes.
Read more ⤵️
www.icr.ac.uk/about-us/icr...
ICR welcomes FDA approval of capivasertib for advanced prostate cancer
ICR welcomes FDA approval of capivasertib for advanced prostate cancer
www.icr.ac.uk
June 18, 2026 at 12:51 PM
📢 New @fda.gov approval for #capivasertib in advanced #ProstateCancer.
The drug, made possible by decades of research at the ICR, helps delay progression in patients with PTEN-deficient disease – an aggressive form with poor outcomes.
Read more ⤵️
www.icr.ac.uk/about-us/icr...
The drug, made possible by decades of research at the ICR, helps delay progression in patients with PTEN-deficient disease – an aggressive form with poor outcomes.
Read more ⤵️
www.icr.ac.uk/about-us/icr...
The FDA approved capivasertib (Truqap) in combination with abiraterone (Zytiga) and prednisone for PTEN-deficient prostate cancer, the agency announced on Friday.
https://www.medpagetoday.com/hematologyoncology/prostatecancer/121742
https://www.medpagetoday.com/hematologyoncology/prostatecancer/121742
FDA Approves Prostate Cancer Combo That Warranted Advisory Meeting
Capivasertib plus abiraterone combination lands indication for PTEN-deficient tumors
www.medpagetoday.com
June 15, 2026 at 9:06 PM
The FDA approved capivasertib (Truqap) in combination with abiraterone (Zytiga) and prednisone for PTEN-deficient prostate cancer, the agency announced on Friday.
https://www.medpagetoday.com/hematologyoncology/prostatecancer/121742
https://www.medpagetoday.com/hematologyoncology/prostatecancer/121742
🟢 #$AZN — FDA Approval
FDA Approval - Truqap + abiraterone first and only targeted treatment for PTEN-deficient mAPMN/S prostate cancer
FDA approved Truqap (capivasertib) in combination with abiraterone and prednisone as the first and only targeted treatment for…
https://biostock.app/symbols/AZN
FDA Approval - Truqap + abiraterone first and only targeted treatment for PTEN-deficient mAPMN/S prostate cancer
FDA approved Truqap (capivasertib) in combination with abiraterone and prednisone as the first and only targeted treatment for…
https://biostock.app/symbols/AZN
June 15, 2026 at 10:57 AM
🟢 #$AZN — FDA Approval
FDA Approval - Truqap + abiraterone first and only targeted treatment for PTEN-deficient mAPMN/S prostate cancer
FDA approved Truqap (capivasertib) in combination with abiraterone and prednisone as the first and only targeted treatment for…
https://biostock.app/symbols/AZN
FDA Approval - Truqap + abiraterone first and only targeted treatment for PTEN-deficient mAPMN/S prostate cancer
FDA approved Truqap (capivasertib) in combination with abiraterone and prednisone as the first and only targeted treatment for…
https://biostock.app/symbols/AZN
for ~1 in 4 guys with metastatic prostate cancer, treatment wasn't tailored to their pten genetic flaw. but now, fda approved a drug combo that finally targets that specific mutation. that's a really important step from a phase 3 trial.
FDA Approves Capivasertib Plus Abiraterone and Prednisone for PTEN-Deficient Prostate Cancer
The U.S. Food and Drug Administration (FDA) has approved capivasertib (Truqap) in combination with abiraterone and prednisone for adults with metastatic hormone-sensitive prostate cancer that has a PT
www.fda.gov
June 15, 2026 at 8:02 AM
for ~1 in 4 guys with metastatic prostate cancer, treatment wasn't tailored to their pten genetic flaw. but now, fda approved a drug combo that finally targets that specific mutation. that's a really important step from a phase 3 trial.
FDA Approves Prostate Cancer Combo That Warranted Advisory Meeting www.medpagetoday.com/hematologyon...
FDA Approves Prostate Cancer Combo That Warranted Advisory Meeting
Capivasertib plus abiraterone combination lands indication for PTEN-deficient tumors
www.medpagetoday.com
June 13, 2026 at 4:43 AM
FDA Approves Prostate Cancer Combo That Warranted Advisory Meeting www.medpagetoday.com/hematologyon...
FDA Approves Prostate Cancer Combo That Warranted Advisory Meeting www.medpagetoday.com/hematologyon...
FDA Approves Prostate Cancer Combo That Warranted Advisory Meeting
Capivasertib plus abiraterone combination lands indication for PTEN-deficient tumors
www.medpagetoday.com
June 13, 2026 at 4:33 AM
FDA Approves Prostate Cancer Combo That Warranted Advisory Meeting www.medpagetoday.com/hematologyon...
PTEN testing = front-line gatekeeper. Quick payoff: implement validated IHC workflows now to identify capivasertib-eligible mCRPC patients faster—PTEN protein loss beats waiting on NGS for many cases. Full breakdown → https://future.xsbrt.com/PTENPathwayFuture Replies/saves welcome #PTEN
June 12, 2026 at 11:02 PM
PTEN testing = front-line gatekeeper. Quick payoff: implement validated IHC workflows now to identify capivasertib-eligible mCRPC patients faster—PTEN protein loss beats waiting on NGS for many cases. Full breakdown → https://future.xsbrt.com/PTENPathwayFuture Replies/saves welcome #PTEN
The @US_FDA approved the targeted therapy capivasertib with the hormone therapy abiraterone and the steroid prednisone for adults with PTEN-deficient metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer: buff.ly/DD3a27z
FDA approves capivasertib with abiraterone and prednisone for PTEN-def
On June 12, 2026, the Food and Drug Administration approved capivasertib (Truqap, AstraZeneca) in combination with abiraterone and prednisone for adults with metastatic androgen pathway…
www.fda.gov
June 12, 2026 at 8:43 PM
The @US_FDA approved the targeted therapy capivasertib with the hormone therapy abiraterone and the steroid prednisone for adults with PTEN-deficient metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer: buff.ly/DD3a27z
🚨 FDA Approves capivasertib Plus Abiraterone as First Targeted Therapy for PTEN-Deficient Metastatic Hormone-Sensitive Prostate Cancer
Source AstraZeneca
www.astrazeneca.com/media-centre...
Source AstraZeneca
www.astrazeneca.com/media-centre...
June 12, 2026 at 7:44 PM
🚨 FDA Approves capivasertib Plus Abiraterone as First Targeted Therapy for PTEN-Deficient Metastatic Hormone-Sensitive Prostate Cancer
Source AstraZeneca
www.astrazeneca.com/media-centre...
Source AstraZeneca
www.astrazeneca.com/media-centre...
Capivasertib available in India: 247qualitymeds.com/product/capi...
Capivasertib
Buy Capivasertib 200 mg or 160 mg tablets in India from 24/7 QualityMeds. Get genuine medicine and cost details by contacting us today at +91 9967979080.
247qualitymeds.com
June 3, 2026 at 11:41 AM
Capivasertib available in India: 247qualitymeds.com/product/capi...